UBS has raised its price target for Sartorius Stedim Biotech from 194 euros to 215 euros after the company's third-quarter figures were released.
The Swiss bank has kept its "Neutral" rating on the stock, with analyst Matthew Weston stating that the revised target is due to higher valuations in the biotechnology sector.
The updated price target reflects a positive outlook for Sartorius Stedim, which has demonstrated resilience in its financial performance.